About Intellect's RECALL-VAX(TM) technology
The key to inactivation of the beta-amyloid toxin by vaccination is to stimulate a strong antibody immune response that specifically targets the toxin. The proprietary RECALL-VAX(TM) technology combines a short fragment of beta-amyloid with part of the tetanus toxoid, against which most people have been vaccinated, to provide B and T-helper epitopes, respectively, while specifically targeting the beta-amyloid toxin. This combination increases the likelihood of generating a robust immune response as a result of the memory imprint created by tetanus toxoid without the danger of contamination from potentially harmful human beta-amyloid T-cell epitopes. The short fragments of beta-amyloid used in RECALL-VAX(TM) ensure that only the toxin, and not the protein from which it is derived, is targeted by the antibodies, and because of their short length, the fragments are incapable of provoking an autoimmune response.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized
by progressive loss of memory and cognition, ultimately leading to complete
debilitation and death. A hallmark feature of Alzheimer's pathology is the
presence of insoluble protein deposits known as beta-amyloid on the surface
of nerve cells, which results from the accumulation of soluble beta-amyloid
in the brain. The effects of the disease are devastating to the patients as
well as the caregivers, with significant associated health care costs. It
is estimated that there are
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2007 PR Newswire.